RIND - Reversible Ischemic Neurological Deficit

Definition

• Lasts longer than 24 hours (distinguishing it from TIA)
• Resolves completely within 21 days (classically) or, in some definitions, within 48 hours to 3 weeks, with no permanent neurological damage

The Cerebrovascular Ischemic Spectrum

"To be considered a TIA, the symptoms must completely resolve within 24 hours. Formerly, if symptoms lasted longer than 24 hours but resolved within 48 hours, the presentation was considered a reversible ischemic neurologic deficit (RIND), although this terminology is falling out of favor." - Current Surgical Therapy, 14e

Etiology & Pathophysiology

1. Atherosclerosis of extracranial carotid/vertebrobasilar arteries (most common)
2. Cardioembolic sources - atrial fibrillation, valvular disease, low ejection fraction, patent foramen ovale
3. Small vessel disease (lacunar)
4. Hypercoagulable states - antiphospholipid antibody syndrome, protein C/S deficiency, factor V Leiden, antithrombin III deficiency, malignancy
5. Arterial dissection (especially in young patients)
6. Vasculitis - SLE, polyarteritis nodosa, temporal arteritis

Clinical Features

• Contralateral hemiparesis/hemiplegia
• Contralateral hemisensory loss
• Aphasia/dysphasia (dominant hemisphere)
• Amaurosis fugax (ipsilateral monocular visual loss)

• Diplopia, vertigo, dysarthria
• Ataxia
• Crossed deficits (ipsilateral cranial nerve + contralateral limb)
• Bilateral weakness or sensory symptoms
• Drop attacks

Why RIND is Obsolete / "Falling Out of Favor"

• DWI-MRI can detect acute infarction within minutes, even in "clinically reversible" events
• Studies show up to 50% of patients with apparent RIND have evidence of infarction on DWI-MRI
• Therefore, clinical resolution does not equal absence of structural brain damage
• The 2009 updated TIA definition (AHA/ASA) shifted to a tissue-based definition: TIA = transient neurological symptoms WITHOUT evidence of infarction on neuroimaging, regardless of duration
• Under this framework, many events previously called RIND are now classified as minor stroke

• TIA (symptom-based, <24 h, no infarct on imaging)
• Minor stroke / Minor ischemic stroke (replaces RIND; NIHSS score ≤3 or 4, good recovery)

Risk After RIND

• ~10-15% risk of completed stroke within 5 years in symptomatic carotid disease patients
• Patients presenting with RIND/TIA warrant urgent evaluation - the ABCD2 score stratifies stroke risk

Investigation

• Urgent neuroimaging: MRI brain with DWI (preferred) or CT scan
• Vascular imaging: MRA/CTA or carotid duplex ultrasound - to assess for carotid stenosis
• Cardiac workup: ECG, echocardiogram (TTE/TEE), 24-48h Holter monitoring
• Bloods: FBC, coagulation screen, lipid profile, glucose, HbA1c, thrombophilia screen (young patients)
• Transcranial Doppler: microemboli detection

Management

• Aspirin (300 mg loading, then 75-100 mg daily)
• Dual antiplatelet therapy (aspirin + clopidogrel) for 21 days after high-risk TIA/minor stroke (CHANCE and POINT trials) - shown to reduce early recurrence

• Aggressive hypertension management
• Statin therapy (reduce stroke risk ~25%)
• Diabetic control, smoking cessation, weight management

• If cardioembolic source identified (e.g., AF) - anticoagulation with DOAC or warfarin

• Carotid endarterectomy (CEA) if symptomatic carotid stenosis ≥50-70% - greatest benefit in symptomatic patients operated on within 2 weeks

Key Points Summary

• RIND = focal neurological deficit lasting >24 h but resolving within 3 weeks, with no permanent damage
• It is an outdated term, largely replaced by "minor stroke" due to MRI evidence showing infarction even when symptoms resolve
• Represents a medical emergency - high short-term stroke risk
• Management: urgent workup, antiplatelet/anticoagulation, vascular surgery if indicated
• Under the tissue-based TIA definition, events with DWI infarction are strokes regardless of clinical resolution

Antidote for Factor Xa Inhibitors

Factor Xa Inhibitors (DOACs)

• Apixaban (Eliquis)
• Rivaroxaban (Xarelto)
• Edoxaban (Savaysa/Lixiana)
• Betrixaban (Bevyxxa)

Specific Antidote: Andexanet Alfa (Andexxa / Ondexxya)

Mechanism of Action

"A recombinant variant of factor Xa without catalytic activity, andexanet serves as a decoy to sequester oral factor Xa inhibitors until they are cleared from the circulation." - Harrison's Principles of Internal Medicine, 22e

Indications

• Life-threatening or uncontrolled major bleeding on rivaroxaban or apixaban
• Intracranial hemorrhage (ICH) - most common indication
• Retroperitoneal, pericardial bleeds (closed space bleeds)
• NOT for urgent/emergency surgery (also reverses heparin/LMWH - problematic for cardiac surgery)
• NOT for GI bleeds controllable by local measures
• NOT for drug overdose without bleeding

Dosing (FDA-Approved)

Harrison's Principles of Internal Medicine, 22e

Key Notes

• Administered as IV bolus followed by continuous infusion over 2 hours
• Expensive - not available at all hospitals
• Not to be combined with other clotting factor products
• Reverses anti-Factor Xa activity rapidly (within minutes of bolus)
• FDA approval based on ANNEXA-4 (prospective cohort) and ANNEXA-I (RCT, 2024)

ANNEXA-I Trial (NEJM, May 2024) - Key Data

• Phase 4 RCT in patients with ICH on Factor Xa inhibitors (n=530)
• Andexanet alfa vs. usual care (typically 4-factor PCC)
• Primary endpoint (hemostatic efficacy): 67% andexanet vs. 53% usual care
• No difference in 30-day mortality or functional outcome (mRS)
• Concern: Higher rate of thrombotic events with andexanet alfa (mechanism: TFPI inhibition + successful reversal of anticoagulation)

Alternative / Non-Specific Reversal: 4-Factor PCC (Kcentra / Beriplex)

• PCC is the preferred alternative when andexanet alfa is unavailable
• Evidence from prospective cohort studies shows effective hemostasis restoration
• Preferred for cardiac/vascular surgery patients needing subsequent heparinization
• Betrixaban and edoxaban - only PCC is recommended (andexanet alfa not FDA-approved for these)

Other Supportive Measures

• Activated charcoal (if last dose within 2-4 hours, no vomiting, no risk of aspiration)
• Hold/discontinue the Factor Xa inhibitor
• IV fluid resuscitation and blood products as needed
• Identify and control the bleeding source
• Coagulation testing: anti-Factor Xa activity (PT/aPTT not reliable for monitoring)
• Assess renal function (renal excretion varies: apixaban 54%, rivaroxaban 73%, edoxaban 56%)

Comparison with Dabigatran (Factor IIa) Reversal

Idarucizumab is a humanized Fab antibody fragment that binds dabigatran with high affinity forming an irreversible complex; given as two 2.5 g IV boluses (5 g total). Dabigatran can also be removed by hemodialysis.

When NOT to Use Andexanet Alfa

• Cardiac surgery patients requiring heparin/LMWH for cardiopulmonary bypass (andexanet also reverses heparin - use PCC instead)
• Emergency surgery or invasive procedures (neither andexanet nor PCC has RCT evidence here)
• Elective surgery or non-life-threatening bleeding
• Overdose without active bleeding